[Randomized double-blind study of the analgesic effect of caerulein and morphine in chronic tumor pain].
Caerulein (CRL) (5 micrograms i.m.) and morphine (10 mg i.m.) have been tested for their analgesic activity in a double blind randomized study in a total of 36 patients with medium to severe tumor pains. A decrease of more than 20 mm on a visual analogue scale (VAS) was taken as a criterion for successful therapy. This was the case in 67% of the patients treated with morphine and 50% of those treated with CRL. This difference is statistically not significant, but CRL has significantly fewer side-effects than morphine. The present data do not permit a definitive judgement on the value of CRL in the treatment of tumor pains. Further studies with more patients and different doses and administration routes are warranted.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002108:Ceruletide / Q000008:administration & dosage*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009020:Morphine / Q000008:administration & dosage*; D009369:Neoplasms / Q000503:physiopathology*; D010146:Pain / Q000188:drug therapy*; D010147:Pain Measurement; D011897:Random Allocation
D009020:Morphine; D002108:Ceruletide
Randomisierte Doppelblindstudie über die analgetische Wirkung von Caerulein und Morphin bei chronischen Tumorschmerzen.